O-GlcNAc as a potential target for disease modifying therapy in Alzheimer disease

被引：0
|
作者：
Vocadlo, David J. [1 ,2 ]
Yuzwa, Scott A. [1 ]
Shan, Xiaoyang [2 ]
Heinonen, Julia [1 ]
Watson, Neil [3 ]
Jones, Bryan [3 ]
Macauley, Matthew S. [1 ]
Gong, Chengxin [4 ]
McEachern, Ernest [1 ]
Yadav, Anuj [1 ]
机构：
[1] Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada
[2] Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada
[3] Simon Fraser Univ, Dept Psychol, Burnaby, BC V5A 1S6, Canada
[4] New York State Inst Basic Res Dev Disabil, Dept Neurochem, Staten Isl, NY 10314 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2013年 / 246卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
215-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [31] O-GlcNAc regulation of autophagy and α-synuclein homeostasis; implications for Parkinson’s disease
    Willayat Y. Wani
    Xiaosen Ouyang
    Gloria A. Benavides
    Matthew Redmann
    Stacey S. Cofield
    John J. Shacka
    John C. Chatham
    Victor Darley-Usmar
    Jianhua Zhang
    Molecular Brain, 10
  • [32] Incretin Mimetics as Potential Disease Modifying Treatment for Alzheimer's Disease
    Crook, Harry
    Edison, Paul
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 101 : S357 - S370
  • [33] Alzheimer disease: From basic study to disease-modifying therapy
    Iwatsubo, Takeshi
    NEUROSCIENCE RESEARCH, 2009, 65 : S4 - S4
  • [34] Disease-modifying therapy for Alzheimer's disease: Challenges and hopes
    Iwata, Atsushi
    Iwatsubo, Takeshi
    NEUROLOGY AND CLINICAL NEUROSCIENCE, 2013, 1 (02): : 49 - 54
  • [35] Possible Consequences of the Approval of a Disease-Modifying Therapy for Alzheimer Disease
    Musiek, Erik S.
    Morris, John C.
    JAMA NEUROLOGY, 2021, 78 (02) : 141 - 142
  • [36] An Interprofessional Team for Disease-Modifying Therapy in Alzheimer Disease Implementation
    Turk, Katherine W.
    Knobel, Mark D.
    Nothern, Alexandra
    Friedman, Garrett
    Noah, Hannah
    Campbell, Brendan
    Anderson, Diana C.
    Charidimou, Andreas
    Mills, Andrew
    Coronel, Vanessa
    Pierre, Nacha
    Reynolds, Beverly V.
    Wagner, Caroline
    Varga, Leanne M.
    Roefaro, John
    Triantafylidis, Laura
    Budson, Andrew E.
    NEUROLOGY-CLINICAL PRACTICE, 2024, 14 (06)
  • [37] O-GlcNAc transferase and O-GlcNAcase: achieving target substrate specificity
    Nagel, Alexis K.
    Ball, Lauren E.
    AMINO ACIDS, 2014, 46 (10) : 2305 - 2316
  • [38] O-GlcNAc transferase and O-GlcNAcase: achieving target substrate specificity
    Alexis K. Nagel
    Lauren E. Ball
    Amino Acids, 2014, 46 : 2305 - 2316
  • [39] Human Alzheimer's disease synaptic O-GlcNAc site mapping and iTRAQ expression proteomics with ion trap mass spectrometry
    Skorobogatko, Yuliya V.
    Deuso, John
    Adolf-Bergfoyle, Jared
    Nowak, Matthew G.
    Gong, Yuesong
    Lippa, Carol Frances
    Vosseller, Keith
    AMINO ACIDS, 2011, 40 (03) : 765 - 779
  • [40] Human Alzheimer’s disease synaptic O-GlcNAc site mapping and iTRAQ expression proteomics with ion trap mass spectrometry
    Yuliya V. Skorobogatko
    John Deuso
    Jared Adolf-Bergfoyle
    Matthew G. Nowak
    Yuesong Gong
    Carol Frances Lippa
    Keith Vosseller
    Amino Acids, 2011, 40 : 765 - 779
12345